Ozempic
FDA Recall NDC 0169-4136
FDA Enforcement Report: View Recall Date, Reasons, and Safety Status
Active & Historical Enforcement Reports
This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.
The FDA has identified 1 recorded enforcement report(s) associated with Ozempic (NDC 0169-4136). A significant event, classified as Class II, was initiated on Mar 22, 2021 by Novo Nordisk Pharmaceutical Industries, Lp. The reported reason for this action was: "Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors."
This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.
This specific recall has a current status of TERMINATED, indicating that the FDA considers the recall process finished or the product successfully recovered.
Reported Recall Events
Class II Terminated
Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.
Mar 22, 2021
Apr 21, 2021
N/A
Recall Profile & Regulatory Data
Event ID
87537
Classification
Class II
Enforcement Status
Terminated
Recalling Firm
Novo Nordisk Inc
Voluntary / Mandated
Voluntary: Firm initiated
Distribution Pattern
Nationwide in the USA
Termination Date
Dec 09, 2022
Product Description
OZEMPIC (semaglutide) injection, 2 mg/1.5 mL (1.34 mg/mL) Prefilled pen, 1 pen, Sample. Not for Resale, Rx only, Novo Nordisk Inc, Plainsboro, NJ 08536, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, NDC 0169-4132-90 (Pen), NDC 0169-4132-97 (Kit)
Batch or Lot Expiration Information
Lot# KP50867, exp 10/31/2022, KP53021, exp 04/30/2023, KP52338, exp 02/28/2023, JP54354, exp 08/31/2022, KP50676, exp 10/31/2022, KP51434, exp 11/30/2022, KP51491, exp 11/30/2022, KP51781, exp 01/31/2023, KP52249, exp 01/31/2023, KP52270, exp 01/31/2023, KP52722, exp 01/31/2023, KP52973, exp 01/31/2023, KP53031, exp 01/31/2023, KP53221, exp 12.04.2023, KP53369, exp 01/31/2023
Affected Packages Involved in this Recall
0169-4136-11Product
0169-4136-02Product
0169-4132-90Product
0169-4132-97Product
0169-4132-11Product
0169-4132-12Product
0169-4130-01Product
0169-4130-13Product
0169-4772-11Product
0169-4772-12Product
0169-4772-90Product
0169-4772-97Product
0169-4181-03Product
0169-4181-13Product
0169-4181-90Product
0169-4181-97Product
0169-1302-01Product
0169-1302-14Product
0169-1302-90Product
0169-1302-94Product
0169-1305-01Product
0169-1305-14Product
0169-1310-01Product
0169-1310-14Product
About FDA Recall Enforcement Reports
FDA recall data documents classified recall actions associated with a product. Most recalls are limited to specific lots, batches, or package configurations rather than every unit of a drug.
If a recall is listed for an NDC, review the affected lot information and package details carefully. Patients and healthcare professionals should confirm whether a specific product in hand matches the lot or package information before assuming it is affected.
